Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled – MS arising during Tocilizumab therapy for rheumatoid arthritis
Restricted accessCase reportFirst published online February, 2016
Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled – MS arising during Tocilizumab therapy for rheumatoid arthritis
This clinical commentary discusses on the potential relationship between multiple sclerosis (MS) and tocilizumab in a patient with rheumatoid arthritis who developed MS while on treatment with this anti-interleukin-6 agent.
CamineroAComabellaMMontalbanX. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story. J Neuroimmunol2011; 234(1–2): 1–6.
2.
MizwickiMTFialaMMagpantayL. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis2012; 1(3): 305–315.
3.
Guerne PA and Carson DA. Lotz M. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol1990; 144(2): 499–505.
